The combination of NUC-3373 plus pembrolizumab was generally well tolerated ... Module 2 included 4 patients with non-small cell lung cancer (NSCLC) or pleural mesothelioma who had disease progression ...

While there are several immunotherapies in development for mesothelioma the Opdivo and ... Opdivo monotherapy and Merck & Co’s Keytruda (pembrolizumab) are also in clinical development.

Keytruda (pembrolizumab) is a prescription drug ... This includes: Malignant pleural mesothelioma: Keytruda is prescribed to adults as a first-choice treatment for malignant pleural mesothelioma ...

Pembrolizumab plus chemotherapy improves disease-free survival (DFS) in patients with high-risk endometrial cancer after surgery with curative intent, according to a study published online Oct. 16 ...

The Institute of Cancer Research, London, has criticised the decision by NICE not to recommend the immunotherapy, pembrolizumab, as a first-line treatment for patients with advanced head and neck ...

Merck (NYSE:MRK) announced Wednesday that a Phase 3 trial designed to test its anti-PD-1 therapy Keytruda (pembrolizumab) as ...

KEYTRUDA plus chemotherapy is the first approval in the EU for an anti-PD-1 therapy combined with chemotherapy only for patients with primary advanced or recurrent endometrial carcinoma regardless ...

This emphasizes a critical issue as pembrolizumab is increasingly being used in early TNBC and could have long-term survivorship implications. Supported in part by The University of Texas MD Anderson ...

“Based on our strong phase 2 clinical data reported previously for petosemtamab in HNSCC both as monotherapy and in combination with pembrolizumab, I continue to be confident that petosemtamab ...